A new study published in Frontiers in Public Health has used data from India's National Family Health Survey (NFHS-5) to develop a composite scoring system that identifies women likely to have polycystic metabolic ovary syndrome (PMOS/PCOS) at the population level. The research, led by scientists at the University of Bergen in Norway, analysed information from nearly 300,000 women aged 20–40 and found that 3.69% fell into a high-score group, 29.41% into a moderate-score group, and 66.90% into a low-score group.
The study is notable because it moves beyond traditional clinical diagnosis — which can be costly and often misses many cases — to create a proxy measure using data already collected in a large, nationally representative survey. The authors constructed three domain-specific scores: one for glucose-related markers, one for anthropometric and metabolic indicators (such as body mass index and waist circumference), and one for ovarian function (based on menstrual history). These were combined into a single PMOS/PCOS-like phenotype score.
According to the study, higher scores were associated with several adverse health outcomes. Women in the high-score group had a greater prevalence of self-reported noncommunicable diseases, including diabetes, cancer, and heart disease. The score was also linked to primary infertility, stillbirth, and caesarean delivery. These findings underscore the metabolic burden that often accompanies PCOS, a condition that has historically been treated primarily as a reproductive and endocrine disorder.
The researchers noted that socioeconomic factors played a role: higher scores were more common among urban, highly educated, and wealthier women. Additionally, states with a higher Human Development Index (HDI) showed a greater prevalence of the high-score group. This pattern may reflect better access to healthcare and diagnosis in more developed regions, but it also raises questions about lifestyle and dietary changes associated with urbanisation and affluence.
The study's authors emphasised that their scoring system is a population-level proxy and not a clinical diagnosis. They pointed out that PCOS remains under-detected and under-treated in India, where prevalence estimates range from 3.7% to 22.5% depending on the diagnostic criteria used. The new scoring approach, they argue, could help identify high-risk women for early intervention, particularly for the metabolic complications that are often overlooked in routine gynaecological care.
For university students in India — especially those studying medicine, public health, or related fields — this research highlights the importance of integrating metabolic screening into women's health programmes. It also demonstrates how large-scale survey data can be repurposed to address diagnostic gaps in resource-limited settings. The study's findings may inform future public health strategies aimed at reducing the long-term burden of PMOS/PCOS, which includes elevated risks for type 2 diabetes, cardiovascular disease, and endometrial cancer.
The authors called for a life-course perspective in clinical care, noting that the associations between the phenotype score and reproductive, maternal, and chronic disease outcomes suggest that early detection and management could improve health trajectories for millions of women.